3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
533
Squamous Cell Carcinoma of Head and Neck
274
Head and Neck Neoplasms
253
Lung Neoplasms
238
Uterine Cervical Neoplasms
178
Stomach Neoplasms
168
Esophageal Neoplasms
160
Nasopharyngeal Carcinoma
123
Urinary Bladder Neoplasms
116
Esophageal Squamous Cell Carcinoma
115
Neoplasms
113
Small Cell Lung Carcinoma
104
Breast Neoplasms
92
Neoplasm Metastasis
90
Ovarian Neoplasms
89
Cholangiocarcinoma
76
Carcinoma, Squamous Cell
76
Pancreatic Neoplasms
72
Biliary Tract Neoplasms
70
Mesothelioma, Malignant
57
Oropharyngeal Neoplasms
56
Carcinoma
55
Adenocarcinoma Of Esophagus
52
Recurrence
47
Parkinson Disease 4, Autosomal Dominant Lewy Body
47
Carcinoma, Ovarian Epithelial
45
Nasopharyngeal Neoplasms
41
Lymphoma
41
Adenocarcinoma of Lung
41
Triple Negative Breast Neoplasms
38
Interventions
camrelizumab
2
apatinib
2
Ramucirumab
2
trifluridine tipiracil drug combination
1
tipiracil
1
irinotecan sucrosofate
1
Trifluridine
1
S 1 (combination)
1
Fluorouracil
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Gastric Adenocarcinoma
×
Cisplatin
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts